INmune Bio, Inc. (NASDAQ:INMB) Receives Average Recommendation of “Hold” from Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned an average rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.00.

Several brokerages have commented on INMB. Wall Street Zen downgraded INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Lucid Cap Mkts upgraded INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a research note on Thursday, June 11th.

INmune Bio Price Performance

INMB stock opened at $1.45 on Tuesday. INmune Bio has a twelve month low of $1.09 and a twelve month high of $11.64. The firm has a market cap of $38.54 million, a PE ratio of -0.87 and a beta of 1.03. The business has a 50 day moving average of $1.38 and a 200 day moving average of $1.47.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Trading of INmune Bio

Institutional investors have recently added to or reduced their stakes in the business. Jain Global LLC purchased a new stake in INmune Bio during the 4th quarter valued at $66,000. Charles Schwab Investment Management Inc. boosted its stake in INmune Bio by 20.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after purchasing an additional 8,427 shares during the last quarter. Bank of Montreal Can purchased a new stake in INmune Bio during the 4th quarter valued at $41,000. Goldman Sachs Group Inc. boosted its stake in INmune Bio by 269.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock valued at $88,000 after purchasing an additional 41,173 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in INmune Bio during the 2nd quarter valued at $52,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.